Tang R, Zhong T, Dang Y, Zhang X, Li P, Chen G
Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Clin Transl Oncol. 2016 Apr;18(4):360-8. doi: 10.1007/s12094-015-1377-9. Epub 2015 Aug 26.
Although miR-203 has been proposed as a relevant biomarker for several cancers, the validated prognostic significance of miR-203 in lung cancer remains obscure. Thus, we aimed to identify the relationship between miR-203 expression and clinicopathological significance in non-small cell lung cancer (NSCLC) patients in the current study.
The expression of miR-203 in 125 cases of NSCLC and their paired adjacent non-cancerous tissues was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Simultaneously, the correlation of miR-203 expression with a variety of clinicopathological factors and patient survival was analyzed. Functionally, in vitro effects of miR-203 on proliferation and viability were explored in lung cancer H460, A549, H1299, PC9 and H292 cells, as assessed by MTS tetrazolium assay and fluorimetric resorufin viability assay, respectively.
The relative level of miR-203 was 6.12 ± 6.25 in NSCLC tissues, remarkably downregulated than that of their paired non-tumorous lung tissues (7.88 ± 5.56, P = 0.019). The area under curve (AUC) of low expression of miR-203 to diagnose NSCLC was 0.622 (95 % CI 0.552-0.692, P = 0.001). MiR-203 expression was negatively correlated to lymphatic metastasis (r = -0.334, P < 0.001), tumor size (r = -0.407, P < 0.001) and clinical TNM stages (r = -0.298, P = 0.001). Furthermore, the survival of the low miR-203 expression group was 4.88 ± 4.38 months, markedly shorter than that of the high expression group (23.35 ± 1.12 months, P < 0.001). The level of miR-203 was an independent prognostic indicator of NSCLC using univariate analysis. MiR-203 mimic could suppress the cell growth of five lung cancer cell lines tested to different degrees in vitro.
MiR-203 could become a prognostic predictor in NSCLC and may be a new target for the molecular therapy of NSCLC patients.
尽管miR - 203已被提出作为多种癌症的相关生物标志物，但miR - 203在肺癌中经过验证的预后意义仍不明确。因此，在本研究中我们旨在确定非小细胞肺癌（NSCLC）患者中miR - 203表达与临床病理意义之间的关系。
采用定量逆转录聚合酶链反应（qRT - PCR）评估125例NSCLC患者及其配对的相邻非癌组织中miR - 203的表达。同时，分析miR - 203表达与多种临床病理因素及患者生存的相关性。在功能方面，分别通过MTS四唑盐检测法和荧光素异硫氰酸荧光素活力检测法，探讨miR - 203对肺癌H460、A549、H1299、PC9和H292细胞增殖和活力的体外影响。
NSCLC组织中miR - 203的相对水平为6.12±6.25，明显低于其配对的非肿瘤肺组织（7.88±5.56，P = 0.019）。miR - 203低表达诊断NSCLC的曲线下面积（AUC）为0.622（95%CI 0.552 - 0.692，P = 0.001）。miR - 203表达与淋巴转移（r = - 0.334，P < 0.001）、肿瘤大小（r = - 0.407，P < 0.001）和临床TNM分期（r = - 0.298，P = 0.001）呈负相关。此外，miR - 203低表达组的生存期为4.88±4.38个月，明显短于高表达组（23.35±1.12个月，P < 0.001）。单因素分析显示miR - 203水平是NSCLC的独立预后指标。miR - 203模拟物在体外可不同程度地抑制所检测的五种肺癌细胞系的细胞生长。
miR - 203可成为NSCLC的预后预测指标，可能是NSCLC患者分子治疗的新靶点。
